Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP645137.RAX8C55HwY5UzYCkCZpvuwWQg6Qj7QE8HQ70xaPxd8-HM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP645137.RAX8C55HwY5UzYCkCZpvuwWQg6Qj7QE8HQ70xaPxd8-HM130_assertion type Assertion NP645137.RAX8C55HwY5UzYCkCZpvuwWQg6Qj7QE8HQ70xaPxd8-HM130_head.
- NP645137.RAX8C55HwY5UzYCkCZpvuwWQg6Qj7QE8HQ70xaPxd8-HM130_assertion description "[We describe two non-small-cell lung cancer (NSCLC) patients in which treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs) gefitinib produced a prolonged control of bone disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP645137.RAX8C55HwY5UzYCkCZpvuwWQg6Qj7QE8HQ70xaPxd8-HM130_provenance.
- NP645137.RAX8C55HwY5UzYCkCZpvuwWQg6Qj7QE8HQ70xaPxd8-HM130_assertion evidence source_evidence_literature NP645137.RAX8C55HwY5UzYCkCZpvuwWQg6Qj7QE8HQ70xaPxd8-HM130_provenance.
- NP645137.RAX8C55HwY5UzYCkCZpvuwWQg6Qj7QE8HQ70xaPxd8-HM130_assertion SIO_000772 18079016 NP645137.RAX8C55HwY5UzYCkCZpvuwWQg6Qj7QE8HQ70xaPxd8-HM130_provenance.
- NP645137.RAX8C55HwY5UzYCkCZpvuwWQg6Qj7QE8HQ70xaPxd8-HM130_assertion wasDerivedFrom befree-2016 NP645137.RAX8C55HwY5UzYCkCZpvuwWQg6Qj7QE8HQ70xaPxd8-HM130_provenance.
- NP645137.RAX8C55HwY5UzYCkCZpvuwWQg6Qj7QE8HQ70xaPxd8-HM130_assertion wasGeneratedBy ECO_0000203 NP645137.RAX8C55HwY5UzYCkCZpvuwWQg6Qj7QE8HQ70xaPxd8-HM130_provenance.